

## Sedana Medical Q3 - Risk for slower sales ramp-up in coming quarters

Redeye lowers its sales estimates for 2022e by 20% from SEK149m to SEK119m. While we see the market for mechanically ventilated patients opting for normalization in 2023, we highlight that UK approval is still not in place, and staffing shortages could linger, negatively affecting Sedana Medical's sales and training activities as we move into the next year. We lower our fair value range somewhat following the report.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

### Attachments

[Sedana Medical Q3 - Risk for slower sales ramp-up in coming quarters](#)